PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding disposes of 2,813 common shares worth $204,863.91PUBT·1 day ago, 04:20 PMPTCT-0.17%
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction DealMarket Beat·Aug 16 at 10:01 AMPTCT-0.17%
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'benzinga_article·Aug 13 at 11:28 AMPTCT-0.17%
Sangamo selects winning bids in Chapter 11 asset auction for USD 163.55 million cash at closePUBT·Aug 12 at 03:28 PMSGMOQ-12.55%LLY+1.57%
PTC Therapeutics to buy Sangamo’s ST-920 Fabry gene therapy program for $111 million upfrontPUBT·Aug 12 at 03:02 PMPTCT-0.17%
Why PTC Therapeutics (PTCT) Is Up 6.7% After Profit Beat, Higher Guidance And New Board AppointmentSimplywall·Aug 12 at 02:36 AMPTCT-0.17%
Top 3 Health Care Stocks You'll Regret Missing This Quarterbenzinga_article·Aug 4 at 05:04 AMPTCT-0.17%SUPN-1.48%
Empowered Funds LLC Sells 192,506 Shares of PTC Therapeutics, Inc. $PTCTMarket Beat·Aug 3 at 02:37 AMPTCT-0.17%STT+1.65%
Sei Investments Co. Raises Stake in PTC Therapeutics, Inc. $PTCTMarket Beat·Aug 2 at 03:56 AMPTCT-0.17%
PTC Therapeutics (NASDAQ:PTCT) Upgraded to "Strong-Buy" at Wall Street ZenMarket Beat·Aug 1 at 12:48 AMPTCT-0.17%
PTC Therapeutics director Hege Elisabeth Sollie-Zetlmayer files initial beneficial ownership statementPUBT·Jul 30 at 08:00 PMPTCT-0.17%
PTC Therapeutics posts corporate presentation highlighting Sephience PKU launch momentumPUBT·Jul 30 at 04:11 PMPTCT-0.17%
PTCT: Q2 2026 revenue surged to $361M with net income of $83.5M and raised full-year guidanceQuartr·Jul 30 at 03:13 PMPTCT-0.17%
